Clinical Trial

Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with previously treated NECTIN4-amplified advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior line of systemic therapy in the advanced/metastatic setting (see inclusion criteria below). The study will comprise of 2 cohorts: Cohort A (non-squamous NSCLC) and Cohort B (squamous NSCLC).
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-16
notable Trial sites reduced: 29 -> 3 locations 2026-04-16
Trial Details
NCT Number NCT06933329
Lead Sponsor BicycleTx Limited
Conditions Non-Small Cell Lung Cancer
Enrollment 73 participants
Start Date 2025-07-18
Primary Completion 2028-08-31 (estimated)
Study Completion 2029-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-04-15